In vivo protection against soman toxicity by known inhibitors of acetylcholine synthesis in vitro.
Soman inhibits the enzyme acetylcholinesterase, essentially irreversibly, producing an accumulation of acetylcholine (ACh) which is responsible for many of its toxic effects. Current approaches to treatment include: (1) atropine, a muscarinic receptor blocker; (2) pyridine-2-aldoxime methylchloride (2-PAM), an enzyme reactivator; and (3) carbamate protection of the enzyme. However, no fully satisfactory regimen has been found, primarily because of the rapid aging process. In this study, compounds known to inhibit ACh synthesis in vitro were evaluated in combination with atropine and 2-PAM so as to assess their potential utility in protection against soman toxicity in rats. Acetylsecohemicholinium (100 micrograms/kg, i.c.v.t., 30 min prior to soman), an inhibitor of high affinity choline uptake (HAChU) and cholineacetyltransferase (ChAT) activity in vitro, enhanced the protective effects of atropine and 2-PAM, reducing the mortality within the first 2 hr following soman. N-Hydroxyethylnaphthylvinylpyridine (NHENVP), a quaternary ChAT inhibitor (1.7 mumol/kg, i.m.), significantly reduced the overall percent mortality due to soman from 80% to 20%. The compound was most effective when administered 2-3 min prior to soman and was effective only by the intramuscular route. N-Allyl-3-quinuclidinol, a potent HAChU inhibitor (1 mumol/kg, i.m.) was the most effective quinuclidine analog evaluated, also reducing the percent mortality for a 24-hr period. Unlike NHENVP, it was most effective when given 30-60 min prior to soman. It is suggested from the data that compounds that disrupt presynaptic ACh synthesis in vitro may prove effective in treating organophosphate poisoning. The results demonstrate interesting differences among the compounds studied and provide insight for the design of protectants against soman toxicity. These findings further underscore the need to examine the structure activity and pharmacokinetic properties of these compounds, i.e. comparison of routes of administration, dose-response relationships, and time to effect.
Sterling
G H
GH
Department of Pharmacology, Hahnemann University School of Medicine, Philadelphia, PA 19102-1192.
Doukas
P H
PH
Sheldon
R J
RJ
O'Neill
J J
JJ
D000109:Acetylcholine / Q000096:biosynthesis; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D002801:Cholinesterase Reactivators / Q000494:pharmacology*; D006426:Hemicholinium 3 / Q000031:analogs & derivatives / Q000494:pharmacology; D007700:Kinetics; D007928:Lethal Dose 50; D008297:Male; D011220:Pralidoxime Compounds / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D012999:Soman / Q000633:toxicity*; D013329:Structure-Activity Relationship
D002801:Cholinesterase Reactivators; D011220:Pralidoxime Compounds; D006426:Hemicholinium 3; C006388:acetyl-seco-hemicholinium-3; D001285:Atropine; D012999:Soman; D000109:Acetylcholine; C028797:pralidoxime